Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck
| Autor: | Sarah A. Taylor, Danika Lew, Roy E. Smith, G. I. Rodriguez, John F. Ensley, David E. Schuller |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Drug Administration Schedule Lethargy Internal medicine medicine Humans Pharmacology (medical) Prior Radiation Therapy Aged Aged 80 and over Pharmacology Chemotherapy business.industry Head and neck cancer Middle Aged medicine.disease Confidence interval Radiation therapy Epidermoid carcinoma Head and Neck Neoplasms Carcinoma Squamous Cell Camptothecin Female Topotecan business medicine.drug |
| Zdroj: | Investigational New Drugs. 14:403-407 |
| ISSN: | 1573-0646 0167-6997 |
| Popis: | Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 evaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink